This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fournier, A. Articles by Clavel-Chapelon, F. Search for Related Content PubMed PubMed Citation Articles by Fournier, A. Articles by Clavel-Chapelon, F. Social Bookmarking                            What's this?

Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor–Defined Invasive Breast Cancer

Agnès Fournier, Alban Fabre, Sylvie Mesrine, Marie-Christine Boutron-Ruault, Franco Berrino, Françoise Clavel-Chapelon

From the Institut National de la Santé et de la Recherche Médicale, Villejuif, France; Institut Gustave Roussy, Villejuif; EA4045, Universite Paris-Sud, Paris, France; and Istituto Nazionale Tumori, Department of Preventive and Predictive Medicine, Milan, Italy

Corresponding author: Françoise Clavel-Chapelon, PhD, Institut National de la Santé et de la Recherche Médicale, ERI 20, EA 4045, Institut Gustave Roussy, 94805 Villejuif Cedex, France; e-mail: clavel{at}igr.fr

Purpose We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer.

Patients and Methods We used data from the French E3N cohort study, with 80,391 postmenopausal women followed for a mean duration of 8.1 years; 2,265 histologically confirmed invasive breast cancers were identified through biennial self-administered questionnaires completed from 1990 to 2002. The relative risks (RRs) were estimated using Cox proportional hazards models.

Results Compared with postmenopausal hormone therapy (HT) never-use, ever-use of estrogen+progesterone was not significantly associated with the risk of any breast cancer subtype, but increasing duration of estrogen+progesterone was associated with increasing risks of lobular (P = .06) and estrogen receptor–positive/progesterone receptor–negative (ER+/PR–; P = .02). Estrogen+dydrogesterone was associated with a significant increase in risk of lobular carcinoma (RR, 1.7; 95% CI, 1.1 to 2.6). Estrogen+other progestagens was associated with significant increases in risk of ductal and lobular carcinomas (RR, 1.6; 95% CI, 1.3 to 1.8; and 2.0; 95% CI, 1.5 to 2.7, respectively), of ER+/PR+ and ER+/PR– carcinomas (RR, 1.8; 95% CI, 1.5 to 2.1; and 2.6; 95% CI, 1.9 to 3.5, respectively), but not of ER–/PR+ or ER–/PR– carcinomas (RR, 1.0; 95% CI, 0.5 to 2.1; and 1.4; 95% CI, 0.9 to 2.0, respectively).

Conclusion The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR–, and to affect both ductal and lobular carcinomas.

Supported by Mutuelle Générale de l’Education Nationale; European Community; French League against Cancer; Gustave Roussy Institute; French Institute of Health and Medical Research; 3M Company; several General Councils of France; Fondation pour la Recherche Médicale; Cancéropôle Région Ile-de-France; Direction Générale de la Santé; Agence Française de Sécurité Sanitaire des Produits de Santé.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. W. Setiawan, K. R. Monroe, L. R. Wilkens, L. N. Kolonel, M. C. Pike, and B. E. Henderson Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study Am. J. Epidemiol., May 15, 2009; 169(10): 1251 - 1259. [Abstract] [Full Text] [PDF]

				L. A. Brinton, D. Richesson, M. F. Leitzmann, G. L. Gierach, A. Schatzkin, T. Mouw, A. R. Hollenbeck, and J. V. Lacey Jr. Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3150 - 3160. [Abstract] [Full Text] [PDF]